Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 12Cisplatin 11Specimen Handling 9Bevacizumab 7Brachytherapy 6Platinum 5Paclitaxel 5Nivolumab 5Magnetic Resonance Spectroscopy 5Human Papillomavirus DNA Tests 5Colposcopy 5Carboplatin 5atezolizumab 4Gemcitabine 4Fulvestrant 4Surveys and Questionnaires 3Radiotherapy 3Radiation Dose Hypofractionation 3Radiation 3Drug Therapy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tisotumab vedotin 2palbociclib 2lenvatinib 2Topotecan 2Restraint, Physical 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Ibuprofen × 90 days × Clear all
NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
39 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡